Zacks: Brokerages Expect Amphastar Pharmaceuticals Inc (AMPH) Will Post Earnings of $0.08 Per Share

Equities research analysts expect that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will announce $0.08 earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Amphastar Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.04 and the highest estimate coming in at $0.11. Amphastar Pharmaceuticals posted earnings per share of $0.11 during the same quarter last year, which would indicate a negative year-over-year growth rate of 27.3%. The business is scheduled to issue its next earnings results on Wednesday, August 8th.

On average, analysts expect that Amphastar Pharmaceuticals will report full year earnings of $0.40 per share for the current year, with EPS estimates ranging from $0.24 to $0.56. For the next financial year, analysts expect that the firm will post earnings of $1.20 per share, with EPS estimates ranging from $0.71 to $1.63. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, May 9th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.13). The firm had revenue of $58.40 million during the quarter, compared to analyst estimates of $60.75 million. Amphastar Pharmaceuticals had a positive return on equity of 3.39% and a negative net margin of 1.50%. The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the company posted $0.09 EPS.

Several equities analysts have commented on AMPH shares. ValuEngine downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, June 21st. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 15th. Finally, BidaskClub upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 19th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Amphastar Pharmaceuticals has a consensus rating of “Hold” and an average target price of $21.33.

Shares of Amphastar Pharmaceuticals traded down $0.23, hitting $17.22, during mid-day trading on Friday, according to MarketBeat Ratings. 120,900 shares of the company were exchanged, compared to its average volume of 134,773. Amphastar Pharmaceuticals has a 1-year low of $14.40 and a 1-year high of $20.45. The company has a quick ratio of 1.53, a current ratio of 2.40 and a debt-to-equity ratio of 0.12. The company has a market cap of $813.41 million, a PE ratio of 45.32, a price-to-earnings-growth ratio of 2.61 and a beta of 1.40.

In other news, CFO William J. Peters sold 3,250 shares of the firm’s stock in a transaction on Monday, July 9th. The shares were sold at an average price of $16.46, for a total value of $53,495.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jack Y. Zhang acquired 25,000 shares of the stock in a transaction dated Tuesday, May 15th. The stock was bought at an average price of $16.08 per share, for a total transaction of $402,000.00. Following the purchase, the chief executive officer now owns 2,065,619 shares of the company’s stock, valued at approximately $33,215,153.52. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 32,649 shares of company stock worth $542,766. 31.50% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the company. KBC Group NV grew its stake in shares of Amphastar Pharmaceuticals by 33.1% in the first quarter. KBC Group NV now owns 61,241 shares of the company’s stock worth $1,148,000 after acquiring an additional 15,225 shares during the last quarter. Prudential Financial Inc. grew its stake in shares of Amphastar Pharmaceuticals by 8.4% in the first quarter. Prudential Financial Inc. now owns 62,380 shares of the company’s stock worth $1,170,000 after acquiring an additional 4,850 shares during the last quarter. Wells Fargo & Company MN lifted its position in Amphastar Pharmaceuticals by 156.1% in the fourth quarter. Wells Fargo & Company MN now owns 176,323 shares of the company’s stock worth $3,392,000 after purchasing an additional 107,486 shares during the period. Alliancebernstein L.P. lifted its position in Amphastar Pharmaceuticals by 148.9% in the fourth quarter. Alliancebernstein L.P. now owns 113,520 shares of the company’s stock worth $2,184,000 after purchasing an additional 67,920 shares during the period. Finally, Mackay Shields LLC bought a new position in Amphastar Pharmaceuticals in the first quarter worth $4,294,000. Institutional investors and hedge funds own 43.59% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

See Also: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply